Atara Biotherapeutics, Inc.

NasdaqGS:ATRA Stock Report

Market Cap: US$68.3m

Atara Biotherapeutics Past Earnings Performance

Past criteria checks 0/6

Atara Biotherapeutics's earnings have been declining at an average annual rate of -1.7%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 63.1% per year.

Key information

-1.7%

Earnings growth rate

18.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate63.1%
Return on equityn/a
Net Margin-6,390.3%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Feb 06

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Oct 17
Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

May 18
Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Feb 13
Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%

Nov 22
Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%

EMA panel backs approval of Atara's Ebvallo for transplant complication

Oct 14

Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre

Sep 28

Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline

Aug 17

Atara adds 16% ahead of Phase 2 data for multiple sclerosis candidate

Jul 12

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Intrinsic Value Is Potentially 42% Above Its Share Price

Jul 03
Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Intrinsic Value Is Potentially 42% Above Its Share Price

Time To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Outlook

May 11
Time To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Outlook

Analysts Are Updating Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Estimates After Its Annual Results

Mar 02
Analysts Are Updating Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Estimates After Its Annual Results

Atara Biotherapeutics: Early Stage Promises, Late Stage Delays

Feb 27

Revenue & Expenses Breakdown
Beta

How Atara Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ATRA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 235-29049235
30 Jun 237-30556270
31 Mar 2357-21561270
31 Dec 2264-22868270
30 Sep 2271-24780282
30 Jun 2272-24881282
31 Mar 2224-35082282
31 Dec 2120-34079282
30 Sep 2113-32873245
30 Jun 217-31868245
31 Mar 214-31165245
31 Dec 200-30764245
30 Sep 200-3046662
30 Jun 200-30171115
31 Mar 200-29877167
31 Dec 190-29180216
30 Sep 190-29281204
30 Jun 190-27979194
31 Mar 190-25675175
31 Dec 180-23170167
30 Sep 180-18661130
30 Jun 180-15955107
31 Mar 180-1354692
31 Dec 170-1194081
30 Sep 170-1023570
30 Jun 170-973168
31 Mar 170-882863
31 Dec 160-792557
30 Sep 160-822559
30 Jun 160-692249
31 Mar 160-651947
31 Dec 150-571742
30 Sep 150-461730
30 Jun 150-411427
31 Mar 150-301218
31 Dec 140-281315
30 Sep 140-21813
30 Jun 140-18710
31 Mar 140-1577

Quality Earnings: ATRA is currently unprofitable.

Growing Profit Margin: ATRA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ATRA is unprofitable, and losses have increased over the past 5 years at a rate of 1.7% per year.

Accelerating Growth: Unable to compare ATRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: ATRA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.